When.com Web Search

  1. Ads

    related to: interleukin 2 cancer treatment

Search results

  1. Results From The WOW.Com Content Network
  2. Lymphokine-activated killer cell - Wikipedia

    en.wikipedia.org/wiki/Lymphokine-activated...

    LAK cells, along with the administration of IL-2 have been experimentally used to treat cancer in mice and humans, but there is very high toxicity with this treatment - Severe fluid retention was the major side effect of therapy, although all side effects resolved after interleukin-2 administration was stopped. Treatment of IL-2 cells by ...

  3. Interleukin 2 - Wikipedia

    en.wikipedia.org/wiki/Interleukin_2

    Interleukin-2 (IL-2) is an interleukin, which is a type of cytokine signaling molecule forming part of the immune system. It is a 15.5–16 kDa protein [ 5 ] that regulates the activities of white blood cells (leukocytes, often lymphocytes ) that are responsible for immunity.

  4. Cancer immunotherapy - Wikipedia

    en.wikipedia.org/wiki/Cancer_immunotherapy

    Interleukin-2 and interferon-α are cytokines, proteins that regulate and coordinate the behavior of the immune system. They have the ability to enhance anti-tumor activity and thus can be used as passive cancer treatments.

  5. Denileukin diftitox - Wikipedia

    en.wikipedia.org/wiki/Denileukin_diftitox

    Denileukin diftitox, sold under the brand name Ontak among others, is an anti-cancer medication used for the treatment of adults with T-cell lymphoma. It is an IL2-receptor-directed cytotoxin. It is an engineered protein combining interleukin-2 and diphtheria toxin. [3]

  6. Biological response modifier - Wikipedia

    en.wikipedia.org/wiki/Biological_response_modifier

    Most BRMs are biopharmaceuticals (biologics), including monoclonal antibodies, interleukin 2, interferons, and various types of colony-stimulating factors (e.g., CSF, GM-CSF, G-CSF). [1] " Immunotherapy makes use of BRMs to enhance the activity of the immune system to increase the body's natural defense mechanisms against cancer", [ 2 ] whereas ...

  7. Bempegaldesleukin - Wikipedia

    en.wikipedia.org/wiki/Bempegaldesleukin

    Bempegaldesleukin (development code NKTR-214) is an experimental anti-cancer drug candidate. It is a PEGylated interleukin-2 (IL-2) acting as a CD122-preferential IL-2 pathway agonist designed to activate and proliferate CD8 + T cells and NK cells. [1] [2] It is being developed by Nektar Therapeutics.

  1. Ad

    related to: interleukin 2 cancer treatment